Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

LENZ Therapeutics (LENZ) EBT (2022 - 2025)

LENZ Therapeutics (LENZ) has disclosed EBT for 4 consecutive years, with -$35.9 million as the latest value for Q4 2025.

  • Quarterly EBT fell 183.72% to -$35.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$81.6 million through Dec 2025, down 68.55% year-over-year, with the annual reading at -$81.6 million for FY2025, 64.01% down from the prior year.
  • EBT for Q4 2025 was -$35.9 million at LENZ Therapeutics, down from -$16.7 million in the prior quarter.
  • The five-year high for EBT was -$10.2 million in Q3 2024, with the low at -$35.9 million in Q4 2025.
  • Average EBT over 4 years is -$18.8 million, with a median of -$15.3 million recorded in 2024.
  • The sharpest move saw EBT soared 51.4% in 2023, then plummeted 183.72% in 2025.
  • Over 4 years, EBT stood at -$26.8 million in 2022, then increased by 29.8% to -$18.8 million in 2023, then skyrocketed by 32.63% to -$12.7 million in 2024, then tumbled by 183.72% to -$35.9 million in 2025.
  • According to Business Quant data, EBT over the past three periods came in at -$35.9 million, -$16.7 million, and -$14.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.